PILA PHARMA, Norra Vallgatan 72, 5 Place, Malmö (2026)

22/05/2026

💬 "Beyond the Horizon: Next-Generation GLP-1's, Alternatives & the Future of Diabetes Care and Metabolic Disorders" 🌟

Earlier this week our CEO Gustav H. Gram was invited to participate on a panel debate at LSX Nordic Congress in Copenhagen, to discuss the current and future developments in therapeutics and infrastructure around , and care! 💡

The main takeaways were:

🚨 is still an issue, but with more solutions coming the opportunities for patients and clinicians will only improve and costs will likely only go one way = down! The holy grail would/could be OTC products for everyday wishing to keep overweight at bay!

🏥 There will be many of patients with obesity and co-related disorders, so a vast array of treatments will be needed whether oral, subcutaneous and targeting different pathways to give based on patient needs!

🎯 Pathways that look beyond GLP1 are increasingly in favour - where the importance on profiles and patient where especially potent anti-inflammatory agents and agents promoting "healthy" that retains more muscle mass, could be the coming wave for partnerships.

Thanks a lot to and panelt participants from Yazen Health (Elin Skoglund), Atrogi (Hamza Bokhari), Novo Nordisk (Simon Regnéll) & SIGRID (Kasper Wickzén)

In PILA PHARMA we're grateful for the opportunity to speak at such events and are keen on voicing our opinion, concerns and views in future sessions!

💫 All in all the panel debate very much confirmed that the participating companies, including PILA PHARMA with its clinical stage oral antagonist will play a part in the future of care.

22/05/2026

📖 AGM 2026 - the shareholders annual gathering 🌟

Earlier this week, PILA PHARMA held its annual general meeting at its offices in Malmö, an annual opportunity for shareholders to meet and discuss with management and board around the status and future of the company! 💡

It was a meeting a good turnout of shareholders, coming with some interesting questions, discussions and great mingle time afterwards! 💬 We hope more shareholders will participate in future meetings and events!

The list of topics and decisions can be found in the press release, in the comments section 📚

08/05/2026

🚨 Reminder! Registration for the annual general meeting on 19 May: Today 08 May, is the last for shareholders registration if shares are held privately!

If you have shares registered by a custodian, registration is due by Tuesday 12 May! 🏦

If you're currently not a shareholder but wish to participate, today is thus the last day to take action! 🌟

💡 In both cases a notice of registration is also required to be sent to [email protected] by Tuesday 12 May!

If you are a shareholder but unable to attend, we highly recommend to sign a power of attorney (Fullmakt) and sent to Chairman of the Board, Dorte X. Gram, equally on [email protected].

All documents and more information can be found on the dedicated AGM webpage.
https://pilapharma.com/arsstamma-2026/

08/05/2026

🚨 Reminder! Registration for the annual general meeting on 19 May: Today 08 May, is the last for shareholders registration if shares are held privately!

If you have shares registered by a custodian, registration is due by Tuesday 12 May! 🏦

If you're currently not a shareholder but wish to participate, today is thus the last day to take action! 🌟

💡 In both cases a notice of registration is also required to be sent to [email protected] by Tuesday 12 May!

If you are a shareholder but unable to attend, we highly recommend to sign a power of attorney (Fullmakt) and sent to Chairman of the Board, Dorte X. Gram, equally on [email protected].

All documents and more information can be found on the dedicated AGM webpage.
https://pilapharma.com/arsstamma-2026/

06/05/2026

🎤 UPCOMING INVESTOR EVENTS AND INTERVIEWS - PRESENTING AT Redeye DIABETES DAY ON 06 MAY

PILA PHARMA will have corporate interviews and presentations at several locations today, May 06, 2026. Please find the links below!

🏥 06 May: Redeye Diabetes Day (in-person and online)
Stockholm, Sweden – 13:15 CEST
Link: https://www.redeye.se/events/1139709/redeye-theme-diabetes-4

💫 06 May: Direkt Studios Interview (Online Recording)
Stockholm, Sweden – Release Time TBA
Link: https://www.youtube.com/direktstudios

📚 06 May: Venture Partner Meeting (in-person, invite only)
Copenhagen, Denmark – 17:00 CEST
Link: https://portal.cvx.vc/event/cvx-partner-meeting-may-2026/

For those who missed the latest interview, it was conducted with BioStock - Connecting Innovation & Capital. Here our CEO Gustav Hanghøj Gram commented on the exposure results from the preclinical study, as well as the path forward to clinical trials in obesity.
Link: https://biostock.se/en/2026/04/pila-pharma-om-de-prekliniska-resultaten-och-vagen-framat/

04/05/2026

🚂 "We keep going, the operational train is moving and we're on the right path"

We recently participated in an night hosted by / Aktieinfo / John Stihøj in , Denmark 🇩🇰

Here our CEO Gustav H. Gram gave an introduction to PILA PHARMA and our innovate pill 💊 solution for and and how it fits in a growing market 🚨

Find the link to the presentation (in Danish) in the comments.

You can also find their latest equity analysis on PILA PHARMA 🌟

21/04/2026

💰 Come join us for an night and introduction to PILA PHARMA and our innovate pill solution for and ! 💊

Tomorrow our CEO Gustav H. Gram will be with Aktieinfo / John Stihøj at their event in , Denmark 🇩🇰

Here he will elaborate on the company and our trajectory going forward in an ever more interesting market 🚨

Please find the latest analysis on PILA PHARMA as well as the link to sign up to tomorrows event, in the comments! 🌟

21/04/2026

PILA PHARMA PUBLISHES ITS ANNUAL REPORT FOR 2025 📖

CEO Gustav H.Gram comments:

"2025 was a year of much activity and positive developments for PILA PHARMA. We started the year with positive developments in our dialogue with various big pharma companies who all vocalized interest in new obesity assets and found interest in our oral, small molecule antagonist.

(...)

We executed a highly oversubscribed rights issue to 293,5%, that including an oversubscription. A clear vote of interest and confidence in the Company, management and the new development plan with obesity studies, in an otherwise challenging public capital market for many.

(...) In the second half of the year, we really got the operational train in movement. We're moving forward and will target clinical "proof of concept". We're currently preparing three different clinical trial applications, with clear focus on the one in people with obesity. We will first evaluate the safety following higher doses and longer treatment in a few people with obesity. Given acceptable safety, the plan will be to enroll more participants to be able to identify possible effects on body weight, whilst also preparing other activities to keep building the data package for XEN-D0501"

Please find the report (in Swedish) in link in comments 📚

17/04/2026

: UPDATE TO PRECLINICAL RAT OBESITY STUDIES - LOW EXPOSURE OF XEN-D0501 COULD EXPLAIN LACK OF EFFECT ON BODYWEIGHT

PILA PHARMA yesterday announced that drug exposure in the obese rat studies was very low and plausibly explains the absence of an effect on body weight.

Read more in the press release in the comments!

27/03/2026

🎤🌟 "The interest is definitely still there for drugs that target other pathways than , to achieve healthy weightloss and tolerable safety profiles"

On the last day of , BioStock - Connecting Innovation & Capital reached out to get our take on the conference, the partnering, the market's appetite for new mechanisms of action outside the GLP-1 sphere and the next milestones for PILA PHARMA! 🎯

Find the interview in the comments! 🤠

PILA PHARMA

22/05/2026

22/05/2026

08/05/2026

08/05/2026

06/05/2026

04/05/2026

21/04/2026

21/04/2026

17/04/2026

27/03/2026

Adress

Webbplats

Aviseringar

Kontakta Affären

Genvägar

Dela

Typ